ReviewNature reviews. Gastroenterology & hepatology2011
Epigenetics and colorectal cancer.
Review in Nature reviews. Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 397 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
397 citing papers in PubMed, 5 syntheses or guidelines pooled it, 749 citations in OpenAlex.
- The mechanisms and drug therapies of colorectal cancer and epigenetics: bibliometrics and visualized analysis.Frontiers in pharmacology · 2024Pooled it
- The Relationship betweenMedicina (Kaunas, Lithuania) · 2022Pooled it
- Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review.BMC cancer · 2020Pooled it
- Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies.International journal of molecular sciences · 2019Pooled it
- Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.European journal of cancer (Oxford, England : 1990) · 2019Pooled it
- Plasma and Urine Metabolite Profiles Impacted by Increased Dietary Navy Bean Intake in Colorectal Cancer Survivors: A Randomized-Controlled Trial.Cancer prevention research (Philadelphia, Pa.) · 2021Trial
- Integrative microbiome-methylome analysis links bacterial taxa to colorectal cancer histological subtypes.mSystems · 2026Article
- Colorectal Cancer in Younger and Elderly Patients: A Real-World Analysis from the Modena Cancer Center.Cancers · 2026Article
- Metabolomic Pattern of Ultra-Processed Food Intake and Risk of Colorectal Cancer Precursors.Gastroenterology · 2026Article
- Calcium hydroxide nanoparticles-induced oxidative stress and mitochondrial impairment drive genomic instability and programmed cell death in colorectal cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comprehensive identification of three key genes and three key DNA methylation CpG sites associated with prognosis and prediction in colon adenocarcinoma.Discover oncology · 2026Article
- Lynch Syndrome: An Update of Underlying Molecular Mechanisms, Phenotypes and Methods to Classify Variants of Uncertain Significance.Biomedicines · 2026Review
- Vitamin D-Related Signaling and Epigenetic Regulation: Evidence from Experimental, Observational, and Interventional Studies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multi-omics clustering combined with multiple machine learning to identify epigenetic features in low-grade glioma patients.Translational cancer research · 2026Article
- METTL3-mediated mJournal of translational medicine · 2026Article
- Signet-Ring Cell Colorectal Cancer and Signet-Ring Cell Component Colorectal Cancer: Do They Differ in Clinical Behavior?Journal of clinical medicine · 2026Article
- Recent research progress and clinical status of immunotherapy for colorectal cancer.Journal of advanced research · 2026Review
- DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.Cancers · 2026Review
- Semaphorin 6D drives anti-tumor type I interferon responses to reprogram the tumor microenvironment in colorectal cancer.Cell death & disease · 2026Article
- The tumor-suppressive function of the unique H domain of FCGBP and its potential as a therapeutic target in colorectal cancer.BMC cancer · 2026Article
337 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. It results from an accumulation of genetic and epigenetic changes in colon epithelial cells, which transforms them into adenocarcinomas. Over the past decade, major advances have been made in understanding cancer epigenetics, particularly regarding aberrant DNA methylation. Assessment of the colon cancer epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has hundreds to thousands of abnormally methylated genes. As with gene mutations in the cancer genome, a subset of these methylated genes, called driver genes, is presumed to have a functional role in CRC. The assessment of methylated genes in CRCs has also revealed a unique molecular subgroup of CRCs called CpG island methylator phenotype (CIMP) cancers; these tumors have a particularly high frequency of methylated genes. These advances in our understanding of aberrant methylation in CRC have led to epigenetic alterations being developed as clinical biomarkers for diagnostic, prognostic and therapeutic applications. Progress in this field suggests that these epigenetic alterations will be commonly used in the near future to direct the prevention and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.